Spaulding Clinical Research has partnered with Clinigene International, part of the Biocon, based in Bangalore, India, to broaden and globalize its research services offering, according to PharmaTimes.
The strategic partnership with Clinigene International establishes a “reliable, trustworthy, and cost-efficient global footprint for clinical pharmacology services,” giving both companies an opportunity to “engage pharmaceutical clients strategically and accelerate first-in-human to proof-of-concept clinical development,” Spaulding said.
While Clinigene can offer preclinical development services through its sister-company Syngene, Spaulding will cover the FIH/SAD/MAD (first in human/ single ascending dose/multiple ascending dose) end.
Clinigene also provides DDI (drug-drug interaction) and proof-of-concept services, backed up by its central and bioanalytical laboratories.
“With Clinigene’s expertise and cost-effective approach to BA/BE [bioavailability.bioequivalence] and Spaulding’s market-leading TQT [cardiac risk] study and Cardiac Core Lab expertise, our clients are able to easily structure a program for their compound that delivers high-value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound,” said Randol Spaulding, chief executive officer of Spaulding Clinical.